Gsk (GSK) Enterprise Value (2009 - 2026)
Gsk (GSK) posted quarterly Enterprise Value of -$4.6 billion for Q2 2026, up 18.9% year-over-year from -$3.9 billion in Q2 2025, and up 7.62% quarter-over-quarter from -$5.0 billion in Q1 2026.
Gsk (GSK) Enterprise Value (2009 - 2026) Analysis & Trends
Gsk's Enterprise Value history runs 18 years deep, the most recent figure standing at -$4.6 billion for Q2 2026.
- In Q2 2026, Enterprise Value rose 18.9% year-over-year to -$4.6 billion; the TTM figure through Jun 2026 stood at -$4.6 billion (up 18.9% YoY), while the FY2025 annual figure was -$5.2 billion, up 10.98% from the prior year.
- Enterprise Value for Q2 2026 stood at -$4.6 billion, up from -$5.0 billion in the prior quarter.
- The five-year high for Enterprise Value was $8.2 billion in Q1 2022, with the low at -$6.4 billion in Q1 2025.
- The 5-year median for Enterprise Value is -$4.8 billion (2023), against an average of -$4.0 billion.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 413.54% in 2022, then plunged 1153.88% in 2023.
- Gsk's Enterprise Value stood at -$5.0 billion in 2022, then grew by 10.8% to -$4.5 billion in 2023, then slumped by 30.45% to -$5.9 billion in 2024, then climbed by 10.56% to -$5.2 billion in 2025, then rose by 12.53% to -$4.6 billion in 2026.
- Business Quant data shows GSK's Enterprise Value at -$4.6 billion in Q2 2026, -$5.0 billion in Q1 2026, and -$5.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.58 Bn |
| Mar 31, 2026 | -4.96 Bn |
| Dec 31, 2025 | -5.24 Bn |
| Sep 30, 2025 | -4.83 Bn |
| Jun 30, 2025 | -5.65 Bn |
| Mar 31, 2025 | -6.38 Bn |
| Dec 31, 2024 | -5.86 Bn |
| Sep 30, 2024 | -5.18 Bn |
| Jun 30, 2024 | -4.37 Bn |
| Mar 31, 2024 | -4.23 Bn |
| Dec 31, 2023 | -4.49 Bn |
| Sep 30, 2023 | -4.86 Bn |
| Jun 30, 2023 | -4.80 Bn |
| Mar 31, 2023 | -4.28 Bn |
| Dec 31, 2022 | -5.03 Bn |
| Sep 30, 2022 | -4.38 Bn |
| Jun 30, 2022 | -382.83 Mn |
| Mar 31, 2022 | 8.17 Bn |
| Dec 31, 2021 | 2.46 Bn |
| Sep 30, 2021 | 3.69 Bn |